Moderna bets on off-the-shelf in vivo CAR-T for autoimmune disease
Moderna disclosed its first in vivo CAR-T program, mRNA-6007, which uses a lipid nanoparticle to deliver CAR-T mRNA to CD4/CD8 T and NK cells to target and deplete pathogenic B cells in autoimmune diseases. Marketed as an off-the-shelf approach, it aims to simplify manufacturing and expand access versus traditional ex vivo CAR-T. The therapy is in early IND-enabling stages and is slated to enter the clinic next year, with lupus and other B-cell–mediated conditions among the initial targets; if successful, it could enable larger-scale development, including future oncology applications.